FimmCyte

FimmCyte AG is a pre-clinical, private biotech based in Zurich/Basel, Switzerland, developing a novel immunotherapy platform targeting fibrosis. Its lead candidate, FMC, is designed for endometriosis, with potential expansion into other fibro-inflammatory conditions like kidney and heart disease. The company has garnered recognition in the Swiss startup ecosystem and secured strategic partnerships and non-dilutive funding to advance its pipeline.

A targeted immunotherapy platform designed to recognize a specific protein overexpressed in fibrotic cells, enabling precise elimination of diseased tissue while sparing healthy areas.

The endometriosis treatment landscape is evolving but still dominated by hormonal therapies and pain management, with few disease-modifying candidates in development. In the broader anti-fibrosis space, FimmCyte would compete with other biotechs developing targeted anti-fibrotics, but its specific immunotherapy approach appears to be first-in-class for this application.